⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KURA News
Kura Oncology, Inc.
Kura Oncology Reports Third Quarter 2025 Financial Results
globenewswire.com
KURA
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
globenewswire.com
KURA
Kura Oncology to Report Third Quarter 2025 Financial Results
globenewswire.com
KURA
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
globenewswire.com
KURA
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
KURA
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
globenewswire.com
KURA
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
globenewswire.com
KURA
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
globenewswire.com
KURA